In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year ...

Jan. 16, 2025 – The FDA has approved the drug Omvoh for treating adults with moderately to severely active Crohn's disease, a type of chronic inflammatory bowel disease.This marks the second ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Whilst Omvoh is not yet approved by the US Food and Drug Administration (FDA) to treat Crohn’s disease, it was approved for ulcerative colitis (UC), another type of inflammatory bowel disease (IBD).

Omvoh is the first IL-23p19 antagonist to demonstrate multi-year, sustained efficacy and safety for both Crohn's disease and ulcerative colitis Advertisement ...

Omvoh targets interleukin-23p19, which contributes to intestinal inflammation. Omvoh is the first biological treatment for Crohn's disease to have disclosed two-year Phase III efficacy data at the ...

This approval is based on positive results from the Phase 3 VIVID-1 study of Omvoh in adults with moderately to severely active Crohn's disease who had an inadequate response, loss of response, or ...

This approval is based on positive results from the Phase 3 VIVID-1 study of Omvoh in adults with moderately to severely active Crohn's disease who had an inadequate response, loss of response, or ...

(2025-01-15 | NYSE:LLY) FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease Stockhouse.com uses cookies on this ...